NCT02866214View on ClinicalTrials.gov

Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Endothelial DysfunctionEndstage Renal Disease
Interventions
DRUG

Febuxostat

Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session

DRUG

Placebo

"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT02866214 - Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. | Biotech Hunter | Biotech Hunter